Locating the source of hyperglycemia: Liver versus muscle

Journal of Diabetes

Volumn 4, Issue 1, 2012, Pages 30-36

  Yu, Haoyong ^a   Zhou, Dequan ^b   Jia, Weiping ^a   Guo, Zengkui ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

Author keywords

Hyperglycemia; Localization; Organ impairment; Type 2 diabetes

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SKELETAL MUSCLE;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL;

EID: 84857438122     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2011.00170.x     Document Type: Article

References (18)

1. Féry F. Role of hepatic glucose production and glucose uptake in the pathogenesis of fasting hyperglycemia in type 2 diabetes: Normalization of glucose kinetics by short-term fasting. J Clin Endocrinol Metab. 1994; 78: 536-42.
2. Bonadonna RC, Del Prato S, Saccomani MP et al. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest. 1993; 92: 486-94.
3. Gerich JE. Control of glycaemia. Baillieres Clin Endocrinol Metab. 1993; 7: 551-86.
4. Heine RJ, Hanning I, Morgan L, Alberti KG. The oral glucose tolerance test (OGTT): Effect of rate of ingestion of carbohydrate and different carbohydrate preparations. Diabetes Care. 1983; 6: 441-5.
5. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007; 30: 89-94.
6. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338: 867-72.
7. Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010; 205: 97-106.
8. He L, Sabet A, Djedjos S et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009; 137: 635-46.
9. Kim YD, Park KG, Lee YS et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008; 57: 306-14.
10. Radziuk J, Zhang Z, Wiernsperger N, Pye S. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes. 1997; 46: 1406-13.
11. Yu B, Pugazhenthi S, Khandelwal RL. Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes. Biochem Pharmacol. 1994; 48: 949-54.
12. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol. 1988; 37: 4353-8.
13. Kranebitter M, Niederwanger A, Tatarczyk T et al. Pioglitazone has direct effects on insulin sensitivity and intracellular lipid content in L6 skeletal muscle cells. Horm Metab Res. 2010; 42: 987-90.
14. Rasouli N, Raue U, Miles LM et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005; 288: E930-4.
15. Zhao Z, Lee YJ, Kim SK et al. Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life Sci. 2009; 84: 688-95.
16. Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. Metabolism. 2003; 52: 1078-83.
17. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002; 51: 797-802.
18. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: What we know and what we need to know. J Clin Endocrinol Metab. 2010; 95: 1566-74.